公开(公告)号：US20110081405A1

公开(公告)日：2011-04-07

申请号：US12896447

申请日：2010-10-01

申请人： Zorka Mikloska ,  Boris Subotic ,  Mladen Zinic

发明人： Zorka Mikloska ,  Boris Subotic ,  Mladen Zinic

IPC分类号： A61K9/127 ,  C01B39/02 ,  A61K33/06 ,  A61K9/14 ,  A61P31/12

CPC分类号： A61K33/06 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/593 ,  A61K45/06 ,  A61K2300/00

摘要： Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2.The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound.The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %).The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).

摘要翻译： 本文提供的抗病毒药物（化合物）由活性物质，活性物质的载体和添加剂组成，用于预防，治疗和/或预分解由单纯疱疹病毒感染引起的疾病的后处理 类型1和/或2.活性物质由纯形式的合成沸石表示，具有限定的晶体结构和化学组成。 活性物质（沸石）的结晶尺寸为0.1-10μm，比表面积为400-1200m 2 / g。 钠离子可以与其他阳离子部分或完全交换。 K +，Ag +，NH4 +，Ca2 +，Mg2 +，Mn2 +，Zn2 +，Cu2 +，Fe2 +和Fe3 +。 活性化合物的载体是具有规则和/或延长活性的有机凝胶，水，油，霜，脂质体和基于脂质体的系统。 活性物质与载体的重量比为5×10-9-10-3，即每克载体为5ng至1mg活性物质。 使用的添加剂是维生素C：维生素C（0-20重量％），维生素E（0-0.01重量％），维生素A（0-1重量％）和维生素D3（0-1重量％）。 这种制剂的功效在体外实验中表明，在不同时间点（与高达92％）相比，预处理，重合或后处理病毒的角质形成细胞单层中HSV-1和HSV-2噬菌斑形成的抑制。

公开(公告)号：US20110217470A1

公开(公告)日：2011-09-08

申请号：US13090960

申请日：2011-04-20

申请人： Cleo Kosanovic ,  Boris Subotic

发明人： Cleo Kosanovic ,  Boris Subotic

IPC分类号： B05D5/00 ,  C09D191/00 ,  B05D7/00 ,  B05D3/00

CPC分类号： C03C17/30 ,  C03C2217/76 ,  C04B41/009 ,  C04B41/4922 ,  C04B41/84 ,  C04B41/46 ,  C04B41/463 ,  C04B33/00 ,  C04B14/00

摘要： The invention relates to a preparation for chemical treatment of glass, ceramic and stone surfaces consisting of esters of fatty acids, monomeric organo-silicon compounds and organic solvents. Glass, ceramic and stone surfaces treated with the invention show excellent hidrophobicity and shine. Furthermore, the application of the invention prevents damages of the treated surfaces caused by abrasion during transport, abiding of fingerprints on the treated surfaces and dust accumulation on the treated surfaces.

摘要翻译： 本发明涉及由脂肪酸，单体有机硅化合物和有机溶剂的酯组成的玻璃，陶瓷和石材表面的化学处理制剂。 用本发明处理的玻璃，陶瓷和石材表面显示出优异的疏水性和光泽。 此外，本发明的应用防止了在运输过程中由磨损引起的处理表面的损坏，在处理过的表面上遵守指纹和处理过的表面上的灰尘积聚。

公开(公告)号：US07074437B2

公开(公告)日：2006-07-11

申请号：US10482875

申请日：2002-07-05

申请人： Robert Basic ,  Mirko Hadzija ,  Boris Subotic

发明人： Robert Basic ,  Mirko Hadzija ,  Boris Subotic

IPC分类号： A61K35/78

CPC分类号： A61K36/185 ,  A61K36/481 ,  A61K36/53 ,  A61K2300/00

摘要： The increased level of glucose in blood is the result of the destruction of β cells of the Islets of Langerhans by autoimmune process in insulin-dependent form of diabetes or a relative lack of insulin in insulin-dependent form of diabetes. Constantly present hyperglycemia in diabetes and a relative lack of insulin aid the development of the neuropathy as a late complication of diabetes. For that purpose, a technical problem was set before the inventor with the request of the reduction of glucose in blood, and stopping of the process of the development of the neuropathy as the consequence of the “long” duration of diabetes. Such a mineral-protein preparation was prepared by which glycemia was successfully regulated, but the process was also stopped by depositing of Ca+ in nerve cells. Those early changes caused by diabetes were successfully stopped, so that the appearance of the neuropathy, as a late complication in diabetes, was postponed. The mineral-protein preparation showed a hypoglycemia effect and stopped the development and progressing of the diabetic neuropathy.

摘要翻译： 血液中葡萄糖水平的增加是胰岛素依赖型糖尿病中自身免疫过程或胰岛素依赖型糖尿病相对缺乏的胰岛素胰岛细胞破坏的结果。 在糖尿病中持续存在高血糖症，相对缺乏胰岛素可帮助神经病发展为糖尿病的晚期并发症。 为此，在发明人之前，要求降低血液中的葡萄糖，并由于“长期”的糖尿病持续时间，停止发展神经病变的过程，就出现了技术问题。 通过这种矿物质蛋白质制剂制备血糖成功调节，但是也通过在神经细胞中沉积Ca ++来停止该过程。 糖尿病引起的早期变化成功地停止了，因此神经病变的出现作为糖尿病的晚期并发症被推迟了。 矿物蛋白制剂显示低血糖作用，阻止糖尿病神经病变的发展和进展。